| Change of Auditor | Nov 11, 2026 | Management or board change | ASX |
|---|
| Change in substantial holding | Nov 9, 2026 | Ownership change notice | ASX |
|---|
| Change of Director's Interest Notice x2 | Nov 9, 2026 | Ownership change notice | ASX |
|---|
| Cleansing Notice | Nov 9, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - PAB | Nov 9, 2026 | Financing | ASX |
|---|
| Letter to Shareholders - Annual General Meeting | Oct 29, 2026 | Meeting notice | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 29, 2026 | Meeting notice | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2026 | Oct 28, 2026 | Quarterly report | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2026 | Oct 28, 2026 | Quarterly report | ASX |
|---|
| RLS-2202 Phase 1a Trial Advances to Cohort 2 | Oct 21, 2026 | Other filings | ASX |
|---|
| RLS-2202 Phase 1a Trial Advances to Cohort 2 | Oct 21, 2026 | Other filings | ASX |
|---|
| Investor Presentation | Oct 12, 2026 | Other filings | ASX |
|---|
| Investor Webinar | Oct 5, 2026 | Other filings | ASX |
|---|
| Date of AGM and Closing Date for Director Nominations | Oct 5, 2026 | Meeting notice | ASX |
|---|
| Notification of cessation of securities - PAB | Sep 30, 2026 | Financing | ASX |
|---|
| Patrys Completes Cohort 1 Dosing and Follow-Up | Sep 28, 2026 | Operations update | ASX |
|---|
| Appendix 4E Variance Report | Sep 28, 2026 | Results | ASX |
|---|
| Annual Report - 30 June 2025 | Sep 28, 2026 | Annual report | ASX |
|---|
| Appendix 4G and Corporate Governance Statement | Sep 28, 2026 | Other filings | ASX |
|---|
| First Participants Dosed in RLS-2202 Phase 1A Clinical Trial | Sep 22, 2026 | Other filings | ASX |
|---|
| PAB Establishes Clinical Advisory Committee | Sep 16, 2026 | Operations update | ASX |
|---|
| Appendix 4E - Preliminary Final Report | Aug 31, 2026 | Results | ASX |
|---|
| Ethics Approval Secured for Phase 1A Clinical Trial | Aug 27, 2026 | Other filings | ASX |
|---|
| Investor Presentation - TechKnow Invest Roadshow | Jul 26, 2026 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2026 | Jul 21, 2026 | Quarterly report | ASX |
|---|
| Patrys Secures 50% Revenue Share in IP Commercialisation | Jul 12, 2026 | Acquisition or disposal | ASX |
|---|
| Patrys advances RLS-2202 toward Phase 1 Clinical Trial | May 19, 2026 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2026 | Apr 29, 2026 | Quarterly report | ASX |
|---|
| $3.2 million Placement to Advance Clinical Trials | Apr 19, 2026 | Financing | ASX |
|---|
| Investor Presentation - Broker Meets Biotech | Mar 30, 2026 | Other filings | ASX |
|---|
| RLS-2201 Manufacturing and Regulatory Pathway Initiated | Mar 10, 2026 | Operations update | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2025 | Feb 26, 2026 | Interim report | ASX |
|---|
| Appointment of Chief Executive Officer | Feb 11, 2026 | Management or board change | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2025 | Jan 29, 2026 | Quarterly report | ASX |
|---|
| Investor Presentation | Jan 27, 2026 | Acquisition or disposal | ASX |
|---|
| Completion of Acquisition and Board Appointments | Jan 27, 2026 | Acquisition or disposal | ASX |
|---|
| Pipeline Expanded with Proprietary Injectable Antipsychotic | Nov 25, 2025 | Acquisition or disposal | ASX |
|---|
| Trading Halt | Nov 23, 2025 | Trading halt or suspension | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2025 | Oct 29, 2025 | Quarterly report | ASX |
|---|
| Patrys Receives R&D Tax Incentive Refund | Oct 29, 2025 | Financing | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Sep 7, 2025 | Meeting notice | ASX |
|---|
| Appendix 4E - Preliminary Final Report | Aug 29, 2025 | Annual report | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2025 | Jul 29, 2025 | Quarterly report | ASX |
|---|
| Entitlement Offer Prospectus | Jul 23, 2025 | Offer document | ASX |
|---|
| Non-Renounceable Entitlement Offer | Jul 23, 2025 | Offer document | ASX |
|---|
| Deed of Release entered into with CEO | Jun 16, 2025 | Management or board change | ASX |
|---|
| Successful Placement and Board Changes | Jun 10, 2025 | Financing | ASX |
|---|
| Reinstatement to Official Quotation | Jun 10, 2025 | Trading halt or suspension | ASX |
|---|
| Suspension from Quotation | Jun 3, 2025 | Trading halt or suspension | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2025 | Apr 30, 2025 | Quarterly report | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2024 | Feb 21, 2025 | Interim report | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2024 | Jan 29, 2025 | Quarterly report | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2024 | Oct 29, 2024 | Quarterly report | ASX |
|---|
| PAT-DX1 clinical development update | Oct 1, 2024 | Other filings | ASX |
|---|
| PAT-DX1 GMP specification testing update | Sep 19, 2024 | Other filings | ASX |
|---|
| Appendix 4E and 2024 Annual Report | Aug 23, 2024 | Annual report | ASX |
|---|
| Further update on PAT-DX1 GMP manufacturing run | Jul 28, 2024 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2024 | Jul 23, 2024 | Quarterly report | ASX |
|---|
| Update on GMP manufacturing run of PAT-DX1 | Jun 30, 2024 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2024 | Apr 29, 2024 | Quarterly report | ASX |
|---|
| Positive preclinical data for deoxymabs in vasculitis | Apr 8, 2024 | Operations update | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2023 | Feb 23, 2024 | Interim report | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2023 | Jan 22, 2024 | Quarterly report | ASX |
|---|
| GMP Production of PAT-DX1 Next Quarter | Dec 12, 2023 | Operations update | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2023 | Oct 19, 2023 | Quarterly report | ASX |
|---|
| Appendix 4E and 2023 Annual Report | Aug 28, 2023 | Annual report | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2023 | Jul 25, 2023 | Quarterly report | ASX |
|---|
| PAT-DX1 GLP toxicology reports received | May 23, 2023 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2023 | Apr 24, 2023 | Quarterly report | ASX |
|---|
| Two new deoxymab patents granted in the USA | Apr 16, 2023 | Other filings | ASX |
|---|
| Updated guidance for PAT-DX1 phase 1 clinical study | Mar 30, 2023 | Guidance | ASX |
|---|
| New PAT-DX3 data demonstrates synthetic lethality | Mar 13, 2023 | Other filings | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2022 | Feb 24, 2023 | Interim report | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2022 | Jan 30, 2023 | Quarterly report | ASX |
|---|
| Response to ASX Price Query | Dec 14, 2022 | Explanation request | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2022 | Oct 27, 2022 | Quarterly report | ASX |
|---|
| PAT DX3 Crosses Blood Brain Barrier in Healthy Animals | Oct 16, 2022 | Other filings | ASX |
|---|
| Appendix 4E and 2022 Annual Report | Aug 30, 2022 | Annual report | ASX |
|---|
| PAT-DX1 From Engineering Run Meets all Specification Tests | Aug 29, 2022 | Other filings | ASX |
|---|
| New Research Grant For Deoxymabs in Metastatic Breast Cancer | Aug 26, 2022 | Other filings | ASX |
|---|
| PAT-DX1/Radiation Combination Improves Brain Cancer Survival | Aug 9, 2022 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2022 | Jul 27, 2022 | Quarterly report | ASX |
|---|
| PAT-DX1 Engineering Run Successfully Completed | Jul 3, 2022 | Other filings | ASX |
|---|
| New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis | Jun 13, 2022 | Other filings | ASX |
|---|
| CBCF funding to support deoxymab brain cancer development | Jun 3, 2022 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2022 | Apr 28, 2022 | Quarterly report | ASX |
|---|
| Stable Cell Line for Production of PAT-DX3 Established | Feb 27, 2022 | Other filings | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2021 | Feb 24, 2022 | Interim report | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2021 | Jan 30, 2022 | Quarterly report | ASX |
|---|
| PAT-DX1 engineering update | Jan 23, 2022 | Other filings | ASX |
|---|
| Rights Issue Results and Shortfall Notification | Dec 2, 2021 | Financing | ASX |
|---|
| Rights Issue Offer Document | Nov 8, 2021 | Financing | ASX |
|---|
| $7.8M Capital Raising | Oct 31, 2021 | Financing | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2021 | Oct 19, 2021 | Quarterly report | ASX |
|---|
| Patrys proof of concept ADC significantly increases survival | Oct 17, 2021 | Other filings | ASX |
|---|
| PAT-DX3 proof of concept as potential ADC targeting antibody | Sep 14, 2021 | Other filings | ASX |
|---|
| Appendix 4E and 2021 Annual Report | Aug 25, 2021 | Annual report | ASX |
|---|
| Market Update - PAT-DX1 Clinical Trial Preparation | Aug 2, 2021 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2021 | Jul 29, 2021 | Quarterly report | ASX |
|---|
| PAT-DX1 Improves Survival in Model of Pancreatic Cancer | Jul 25, 2021 | Other filings | ASX |
|---|
| Full size deoxymab PAT-DX3 crosses the blood brain barrier | Jul 11, 2021 | Other filings | ASX |
|---|
| Response to ASX Query | Jun 23, 2021 | Explanation request | ASX |
|---|
| Paper highlights PAT-DX1 as potential brain cancer treatment | Jun 15, 2021 | Other filings | ASX |
|---|
| Patrys receives R&D Tax Incentive refund | Jun 9, 2021 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2021 | Apr 27, 2021 | Quarterly report | ASX |
|---|
| New United States patent granted for Patrys deoxymab assets | Mar 30, 2021 | Other filings | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2020 | Feb 19, 2021 | Interim report | ASX |
|---|
| Patrys Successfully Establishes PAT-DX1 Stable Cell Line | Feb 9, 2021 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2020 | Jan 27, 2021 | Quarterly report | ASX |
|---|
| $7.3M Capital Raising | Nov 8, 2020 | Financing | ASX |
|---|
| Investor Presentation - November 2020 - Updated | Nov 5, 2020 | Other filings | ASX |
|---|
| Investor Presentation - November 2020 | Nov 4, 2020 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2020 | Oct 25, 2020 | Quarterly report | ASX |
|---|
| First patent granted for Deoxymab-nanoparticles | Oct 5, 2020 | Other filings | ASX |
|---|
| Patrys adds full human antibody to Deoxymab portfolio | Sep 27, 2020 | Other filings | ASX |
|---|
| Appendix 4E and 2020 Annual Report | Aug 24, 2020 | Annual report | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2020 | Jul 30, 2020 | Quarterly report | ASX |
|---|
| $4.29 Million Fully Underwritten Rights Issue | Jun 22, 2020 | Financing | ASX |
|---|
| Investor Presentation - June 2020 | Jun 17, 2020 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2020 | Apr 26, 2020 | Quarterly report | ASX |
|---|
| PAT-DX1 mechanism for crossing blood brain barrier confirmed | Mar 15, 2020 | Other filings | ASX |
|---|
| PAT-DX1-NP crosses BBB and targets tumours | Mar 1, 2020 | Other filings | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2019 | Feb 24, 2020 | Interim report | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2019 | Jan 29, 2020 | Quarterly report | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2019 | Oct 28, 2019 | Quarterly report | ASX |
|---|
| Appendix 4E and 2019 Annual Report | Aug 22, 2019 | Annual report | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2019 | Jul 29, 2019 | Quarterly report | ASX |
|---|
| PAT-DX1 significantly improves survival in aggressive GBM | Jul 21, 2019 | Other filings | ASX |
|---|
| Europe grants patent for Deoxymab 3E10 | Jul 17, 2019 | Other filings | ASX |
|---|
| PAT-DX1 Reduces Brain Metastases, Enhances Radiation Therapy | May 29, 2019 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2019 | Apr 23, 2019 | Quarterly report | ASX |
|---|
| Market Update | Mar 29, 2019 | Other filings | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2018 | Feb 20, 2019 | Interim report | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2018 | Jan 30, 2019 | Quarterly report | ASX |
|---|
| PAT-DX1 Suppresses Breast Cancer Brain Metastases | Dec 19, 2018 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2018 | Oct 30, 2018 | Quarterly report | ASX |
|---|
| Settlement of Manufacturing Claims | Oct 24, 2018 | Other filings | ASX |
|---|
| PAT-DX1 Clinical Target Indications Confirmed | Oct 4, 2018 | Other filings | ASX |
|---|
| Patrys and WEHI Awarded Grant | Aug 28, 2018 | Other filings | ASX |
|---|
| Appendix 4E and 2018 Annual Report | Aug 24, 2018 | Annual report | ASX |
|---|
| Patent Granted for Pre-clinical IgM Candidate PAT-LM1 | Aug 1, 2018 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2018 | Jul 25, 2018 | Quarterly report | ASX |
|---|
| Preliminary PAT-DX1 pharmacokinetics | Jul 5, 2018 | Other filings | ASX |
|---|
| China and Japan both grant patents for Deoxymab 3E10 | Jul 3, 2018 | Other filings | ASX |
|---|
| PAT-DX1 Targets and Kills Brain Cancer Stem Cells | May 30, 2018 | Other filings | ASX |
|---|
| Patrys Increases Capital Raising to $4.6 million | May 20, 2018 | Financing | ASX |
|---|
| New Pre-Clinical Collaboration on PAT-DX1 | May 16, 2018 | Other filings | ASX |
|---|
| Patrys Completes $3.5M Placement | May 15, 2018 | Financing | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2018 | Apr 26, 2018 | Quarterly report | ASX |
|---|
| PAT-DX1 Improves Survival in Animal Model of Glioblastoma | Mar 18, 2018 | Other filings | ASX |
|---|
| PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size | Feb 27, 2018 | Other filings | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2017 | Feb 23, 2018 | Interim report | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2017 | Jan 31, 2018 | Quarterly report | ASX |
|---|
| Publication and Patent Filing for Humanized Version of 3E10 | Jan 30, 2018 | Other filings | ASX |
|---|
| PAT-DX1-NP Localizes to Lymph Node Metastases | Jan 28, 2018 | Other filings | ASX |
|---|
| Entitlement Offer Booklet | Jan 14, 2018 | Financing | ASX |
|---|
| PAT-DX1 is synergistic with PARP inhibitor | Dec 10, 2017 | Other filings | ASX |
|---|
| Collaboration with WEHI | Nov 15, 2017 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2017 | Oct 27, 2017 | Quarterly report | ASX |
|---|
| PAB and Garvan Institute of Medical Research Awarded Grant | Oct 15, 2017 | Other filings | ASX |
|---|
| US Patent Granted for Preclinical Candidate PAT-LM1 | Oct 11, 2017 | Other filings | ASX |
|---|
| PAT-DX1 Conjugated to Nanoparticles, Targets Tumors | Sep 17, 2017 | Other filings | ASX |
|---|
| PAT-DX1 Active in Pre-clinical Cancer Models | Sep 13, 2017 | Other filings | ASX |
|---|
| Appendix 4E and 2017 Annual Report | Aug 29, 2017 | Annual report | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2017 | Jul 26, 2017 | Quarterly report | ASX |
|---|
| Patrys Deoxymab 3E10 patent granted in the U.S. | Jul 12, 2017 | Other filings | ASX |
|---|
| PAB Licences Deoxymab 3E10 - nanoparticle IP from Yale | Jun 12, 2017 | Other filings | ASX |
|---|
| Finance Update | Apr 30, 2017 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2017 | Apr 26, 2017 | Quarterly report | ASX |
|---|
| Deoxymab 3E10 lead candidate confirmed | Apr 19, 2017 | Other filings | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2016 | Feb 22, 2017 | Interim report | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2016 | Jan 17, 2017 | Quarterly report | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2016 | Oct 28, 2016 | Quarterly report | ASX |
|---|
| Appendix 4E and 2016 Annual Report | Aug 30, 2016 | Annual report | ASX |
|---|
| Appendix 4C - Quarterly - 30 June 2016 | Jul 27, 2016 | Quarterly report | ASX |
|---|
| Appendix 4C - Quarterly - 31 March 2016 | Apr 20, 2016 | Quarterly report | ASX |
|---|
| Publication on PAT-SM6 Combination Therapy | Apr 5, 2016 | Other filings | ASX |
|---|
| Patrys Provides Update on CEO Position | Mar 30, 2016 | Other filings | ASX |
|---|
| Patrys Acquires Novel Assets from Yale University | Mar 28, 2016 | Acquisition or disposal | ASX |
|---|
| Appendix 4D - Half Year Accounts - 31 December 2015 | Feb 24, 2016 | Interim report | ASX |
|---|
| Appendix 4C - Quarterly - 31 December 2015 | Feb 11, 2016 | Quarterly report | ASX |
|---|
| Appendix 4C - Quarterly - 30 September 2015 | Feb 10, 2016 | Quarterly report | ASX |
|---|